Sandy Srinivas
Publications
- A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2013; (2): 100-6
- Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013; (4): 412-9
- Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013; (2): 181-6
- Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol. 2013; (3): 379-85
- Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013; (1): 215-24
- Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol. 2012; (9): 927-35
- Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012; (9): 1081-7
- Variations in normal serum alpha-fetoprotein (AFP) levels in patients with testicular cancer on surveillance. Onkologie. 2012; (10): 588-91
- mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. PLoS One. 2012; (11): e49144
- Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011; (3): 626-30
- NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy J Natl Compr Canc Network. 2011: 29
- Oral enzastaurin in prostate cancer: a two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease. Invest New Drugs. 2011; (6): 1441-8
- Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol. 2011; (10): e266-7
- Toxicities of targeted agents in advanced renal cell carcinoma. Curr Clin Pharmacol. 2011; (3): 181-8
- Adjuvant Docetaxel and androgen deprivation therapy in patients with High Risk Prostate Cancer Open Prostate Cancer Journal. 2010: 99-104
- NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010; (2): 162-200
- Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res. 2010; (10): 2906-14
- Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU Int. 2010; (11): 1805-11
- The bevacizumab experience in advanced renal cell carcinoma. Onco Targets Ther. 2010: 179-89
- A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma. Chemotherapy. 2009; (5): 321-6
- A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res. 2009; (9): 3605-10
- Combination therapy with calcitriol and non-steroidal anti-inflammatory drugs in the treatment of prostate cancer Dermato Endocrinolgy. 2009: 7-11
- High dose chemotherapy followed by stem cell rescue for high risk germ cell tumors: the Stanford experience. Bone Marrow Transplant. 2009; (7): 547-52
- Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma. Cancer Invest. 2009; (8): 851-6
- Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermatoendocrinol. 2009; (1): 7-11
- Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol. 2009; (6): 338-43
- Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009; (25): 4068-75
- Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008; (9): 1613-8
- Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer. Onkologie. 2008; (8-9): 432-3
- Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer. 2008; (1): 72-7
- The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer. Am J Clin Oncol. 2008; (5): 417-23
- Acute pancreatitis associated with sorafenib. South Med J. 2007; (9): 909-11
- Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2007; (12): 1749-61
- Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007; (7): 650-83
- Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007; (29): 4536-41
- Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. Nutr Rev. 2007; (8 Pt 2): S113-5
- Bone related events in high risk prostate cancer. J Urol. 2006; (6 Pt 2): S50-4
- Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int. 2006; (1): 69-75
- Nonplatinum therapy in advanced bladder cancer. Expert Rev Anticancer Ther. 2006; (6): 887-94
- Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. Urology. 2006; (5): 1001-6
- Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade. Urology. 2006; (6): 1229-34
- A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU Int. 2005; (4): 536-9
- A nonplatinum combination in metastatic transitional cell carcinoma. Am J Clin Oncol. 2005; (2): 114-8
- Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. J Clin Oncol. 2005; (28): 7224-5
- Node Positive Bladder Cancer Arab J Urology. 2005: 7-11
- Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily. J Androl. 2004 Jul-Aug; (4): 630-4
- Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis. Urology. 2004; (4): 808-9
- Positron emission tomography in the initial staging of esophageal cancer. Arch Surg. 2002; (9): 1001-6; discussion 1006-7
- Utility of bone scan post primary therapy in prostate cancer UroOncology. 2002: 37-39
- Management choices in stage I non-seminomatous Germ Cell Tumor UroOncology. 2001: 1-4
- Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 2001; (1): 127-32
- Comparison of FDG-PET and Bone Scans for Detecting Skeletal Metastases in Patients with Non-small Cell Lung Cancer. Clin Positron Imaging. 2000; (3): 97-105
- High-dose chemotherapy in poor-risk germ-cell tumors. Oncology (Williston Park). 2000; (10): 1419-23; discussion 1427-30, 1433-4
- Spontaneous pneumothorax in malignancy: a case report and review of the literature. Ann Oncol. 2000; (7): 887-9
- Actinomycin D revisited in testicular cancer. A case report. Tumori. 1999 Jan-Feb; (1): 78-9
- Tool support for authoring eligibility criteria for cancer trials. Proc AMIA Symp. 1999: 369-73
- Methotrexate tolerance in patients with ileal conduits and continent diversions. Cancer. 1998; (6): 1134-6
- Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol. 1996; (5): 1617-25
- The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995; (8): 1428-34
- Intravenous heparin dosing: patterns and variations in internists' practices. J Gen Intern Med. 1993; (10): 536-42
- The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med. 1993; (9): 874-81

